Modulation of Tissue Sodium in Hemodialysis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-05-15

Study Completion Date

2022-09-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Salt (NaCl) intake is implicated in causing hypertension and cardiovascular disease, the commonest cause of death worldwide. The investigators recently established that Na+ is stored in tissues, bound to glycosaminoglycans (GAGs) in skin and muscle. The resulting local hypertonicity leads to immune cell-driven induction of local tissue electrolyte clearance via modulation of cutaneous lymph capillary density. To visualize these complex processes in man directly, the investigators established Na+ magnetic resonance imaging (23Na-MRI) and investigated Na+ stores in hemodialysis (HD) patients. Hemodialysis patients were sodium-"overloaded" and HD treatment lowered tissue Na+ stores in this study. The observed effects were highly variable and independent of Na+ or water removal from the body during a dialysis session. Tissue Na+ mobilization correlated with circulating vascular endothelial growth factor-C (VEGF-C). The investigators believe that excessive Na+ storage is a reversible condition and therefore susceptible for therapeutic interventions. The investigators hypothesize that lowering dialysate Na+ concentration may favorably affect accelerated tissue Na+ accumulation in hemodialysis patients. Besides, improved tissue Na+ storage, osmostress-induced as well as pro-inflammatory immune cell response should be affected by such a revised dialysis management.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease

NCT04067752

End-stage Renal Disease

COMPLETED NA

Renal Denervation in Chronic Kidney Disease - RDN-CKD Study

NCT04264403

Uncontrolled Hypertension Renal Denervation Chronic Kidney Disease stage3

ACTIVE_NOT_RECRUITING NA

Mechanisms and Treatment of Intradialytic Hypertension - Sodium

NCT01371890

Hemodialysis End-stage Renal Disease Hypertension +1 more

COMPLETED

Dietary Sodium (DS) Intervention to Reduce Volume Overload and Tissue Sodium in Magnetic Resonance Imaging (MRI) for Hemodialysis (HD) Patients

NCT03189758

Kidney Failure, Chronic Dietary Modification

UNKNOWN NA

Dietary Sodium-Restriction (DIS) and Renal Meals (RM) for Hemodialysis (HD)(DISaRM-HD)

NCT04991441

Kidney Failure, Chronic Dietary Modification

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To evaluate effects of moderate reduction of dialysate Na+ concentration on tissue Na+ content the investigators intend to recruit 40 hemodialysis patients, who will be offered a therapeutic change of their dialysate Na+ concentration. After detection of tissue Na+ content using 23Na-MRI technique, the applied dialysate \[Na+\] will be initially increased stepwise by 2 mmol/l per week from 138 to 142 mmol/l and maintained for a period of 5 weeks. After another 23Na-MRI measurement, dialysate \[Na+\] will then be lowered stepwise by 1-2 mmol/l per week to a minimum of 135 mmol/l, which will be also maintained for a period of 5 weeks followed by a final 23Na-MRI assessment.

Hypothesis: Reduction of dialysate Na+ concentration will decrease tissue sodium storage.

Additionally, the investigators will assess changes in body fluid distribution by bioimpedance spectroscopy. Furthermore, vascular compliance in response to the modulation of dialysate \[Na+\] and its correlation with tissue Na+ will be assessed. To investigate the immune response to tissue Na+ accumulation, the osmostress-induced as well as pro-inflammatory immune cell response of isolated monocytes will be quantified.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease Requiring Chronic Dialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dialysate [Na+] 138 mmol/l

Intervention: Change of dialysate \[Na+\] from 138 mmol/l to 142 mmol/l The dialysate \[Na+\] will be increased by 2 mmol/l per week and kept constant for 5 weeks (altogether 6 weeks). Before and after intervention tissue \[Na+\] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.

Group Type ACTIVE_COMPARATOR

Change of dialysate [Na+]

Intervention Type PROCEDURE

Stepwise modulation of dialysate sodium concentration by 1-2 mmo/l per week

dialysate [Na+] 142 mmol/l

Intervention: Change of dialysate \[Na+\] from 142 mmol/l to 135 mmol/l The dialysate \[Na+\] will be decreased by 2 mmol/l per week for 3 weeks and by 1mmol/l for 1 further week. Afterwards the dialysate \[Na+\] will be kept constant for 5 weeks (altogether 8 weeks). Before and after intervention tissue \[Na+\] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.

Group Type ACTIVE_COMPARATOR

Change of dialysate [Na+]

Intervention Type PROCEDURE

Stepwise modulation of dialysate sodium concentration by 1-2 mmo/l per week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Change of dialysate [Na+]

Stepwise modulation of dialysate sodium concentration by 1-2 mmo/l per week

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic Kidney Disease Stage 5D, hemodialysis performed for at least 6 months, three times hemodialysis per week, signed informed consent

Exclusion Criteria

* Pregnancy, severe heart failure (NYHA III - IV), severe liver disease (CHILD C), acute infection, pacemaker or other non-MRI suitable conditions, hyponatremia \< 132 mmol/l

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No